Drug intelligence / Profile preview

18F-OGA-1

Development stage: Preclinical
Lead developer: National Institute of Mental Health
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-OGA-1 is a radiopharmaceutical agent developed for positron emission tomography (PET) imaging. It targets O-linked-β-N-acetyl-glucosamine hydrolase (OGA) in the brain, an enzyme involved in the posttranslational modification of tau protein, which is a biomarker in Alzheimer's disease. OGA inhibition is believed to reduce tau aggregation, which is associated with neurodegenerative diseases. With a half-life of approximately 110 minutes, this fluorine-18 labeled compound is suitable for diagnostic neuroimaging applications.

Other names: [18F]OGA-1

Targets

OGA (Protein O-GlcNAcase)

Beyond the preview

Go deeper on 18F-OGA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-OGA-1.

Explore the full profile